WO2012156419A3 - Lmna, fnta and face-1 activators for preventing and/or attenuating skin ageing and/or hydrating skin - Google Patents

Lmna, fnta and face-1 activators for preventing and/or attenuating skin ageing and/or hydrating skin Download PDF

Info

Publication number
WO2012156419A3
WO2012156419A3 PCT/EP2012/059060 EP2012059060W WO2012156419A3 WO 2012156419 A3 WO2012156419 A3 WO 2012156419A3 EP 2012059060 W EP2012059060 W EP 2012059060W WO 2012156419 A3 WO2012156419 A3 WO 2012156419A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
fnta
lmna
preventing
face
Prior art date
Application number
PCT/EP2012/059060
Other languages
French (fr)
Other versions
WO2012156419A2 (en
Inventor
Christelle Lasserre
Fedorova Elena
Original Assignee
Chanel Parfums Beaute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chanel Parfums Beaute filed Critical Chanel Parfums Beaute
Publication of WO2012156419A2 publication Critical patent/WO2012156419A2/en
Publication of WO2012156419A3 publication Critical patent/WO2012156419A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the identification and the use of compounds which activate the expression of at least one gene selected from LMNA, FNTA and FACE-1, for preventing and/or attenuating ageing, and/or for hydrating skin. The invention thus relates to an in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, comprising the following steps: a. bringing at least one test compound in contact with a sample of keratinocytes; b. measuring the expression of at least one gene selected from LMNA, FACE-1 and FNTA, in said keratinocytes; c. selecting the compounds for which an activation of at least 1.6 fold of the expression of at least one of said genes is measured in the keratinocytes treated in a. compared with the untreated keratinocytes.
PCT/EP2012/059060 2011-05-17 2012-05-15 Lmna, fnta and face-1 activators for preventing and/or attenuating skin ageing and/or hydrating skin WO2012156419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486856P 2011-05-17 2011-05-17
US61/486,856 2011-05-17

Publications (2)

Publication Number Publication Date
WO2012156419A2 WO2012156419A2 (en) 2012-11-22
WO2012156419A3 true WO2012156419A3 (en) 2013-03-28

Family

ID=46168431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/059060 WO2012156419A2 (en) 2011-05-17 2012-05-15 Lmna, fnta and face-1 activators for preventing and/or attenuating skin ageing and/or hydrating skin

Country Status (1)

Country Link
WO (1) WO2012156419A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745755B2 (en) 2014-09-26 2020-08-18 Chanel Parfums Beaute Sestrin activators for preventing and/or attenuating skin ageing and/or hydrating the skin and/or for regulating skin pigmentation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008178390A (en) * 2006-12-27 2008-08-07 Nippon Menaade Keshohin Kk Method of evaluating skin condition and application of the same
US20100159045A1 (en) * 2007-06-11 2010-06-24 Chanel Parfums Beaute Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function
WO2010098595A2 (en) * 2009-02-27 2010-09-02 Amorepacific Corporation Composition for skin external applicationcontaining red pine root extract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008178390A (en) * 2006-12-27 2008-08-07 Nippon Menaade Keshohin Kk Method of evaluating skin condition and application of the same
US20100159045A1 (en) * 2007-06-11 2010-06-24 Chanel Parfums Beaute Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function
WO2010098595A2 (en) * 2009-02-27 2010-09-02 Amorepacific Corporation Composition for skin external applicationcontaining red pine root extract

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. K. AGARWAL ET AL: "Severe Mandibuloacral Dysplasia-Associated Lipodystrophy and Progeria in a Young Girl with a Novel Homozygous Arg527Cys LMNA Mutation", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 93, no. 12, 1 January 2008 (2008-01-01), pages 4617 - 4623, XP055036512, ISSN: 0021-972X, DOI: 10.1210/jc.2008-0123 *
DAYLE MCCLINTOCK ET AL: "The Mutant Form of Lamin A that Causes Hutchinson-Gilford Progeria Is a Biomarker of Cellular Aging in Human Skin", PLOS ONE, vol. 2, no. 12, 5 December 2007 (2007-12-05), pages E1269, XP055031882, DOI: 10.1371/journal.pone.0001269 *
FEDOROVA ELENA ET AL: "Do Changes in Nuclear Architecture Elements Correlate with Skin Aging?", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 131, no. Suppl. 2, September 2011 (2011-09-01), & 41ST ANNUAL MEETING OF THE EUROPEAN-SOCIETY-FOR-DERMATOLOGICAL-RESEARCH; BARCELONA, SPAIN; SEPTEMBER 07 -10, 2011, pages S58, XP002679282 *
R. LEE ET AL: "Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes", HUMAN MOLECULAR GENETICS, vol. 19, no. 8, 15 April 2010 (2010-04-15), pages 1603 - 1617, XP055036511, ISSN: 0964-6906, DOI: 10.1093/hmg/ddq036 *
Y. WANG ET AL: "Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin", HUMAN MOLECULAR GENETICS, vol. 17, no. 15, 17 April 2008 (2008-04-17), pages 2357 - 2369, XP055031880, ISSN: 0964-6906, DOI: 10.1093/hmg/ddn136 *

Also Published As

Publication number Publication date
WO2012156419A2 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
EP3081163A3 (en) Module, device and method for optical measurement
WO2012120288A3 (en) Method, array and use for determining the presence of pancreatic cancer.
WO2014074648A3 (en) Riboregulator compositions and methods of use
WO2015067969A3 (en) Method, array and use thereof for determining pancreatic cancer
EP4249605A3 (en) Methods for analyte detection
BRPI0919896A2 (en) methods for the separation, characterization and / or identification of microorganisms by mass spectroscopy.
WO2010144150A3 (en) Real-time analytical methods and systems
WO2012094580A3 (en) Compounds that modulate oxidative stress
EP2261656A4 (en) Dry test instrument, method of measuring metal and method of producing dry test instrument
BRPI0918217A2 (en) process for measuring the interior of an airplane.
BRPI0906673A2 (en) aqueous dispersion, process for preparing an aqueous dispersion, use of an aqueous dispersion, and, product
WO2011034935A3 (en) Transcription biomarkers of biological responses and methods
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
BR112014028638A2 (en) integrated test and manufacturing process platform.
EP3101407A4 (en) Protectant for electron microscope observation of hydrated biological sample, kit for electron microscope observation, method for observation, diagnosis, evaluation, or quantification by electron microscope, and sample stage
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
SG11201502702SA (en) Refractive index sensor for analyzing an analyte, and method of fabrication thereof
MX2014000537A (en) Method for assessing condition of skin and/or scalp.
CA2879825A1 (en) Torsional and lateral stiffness measurement
WO2015059487A3 (en) Detection of cleavage activity of an enzyme
WO2012164525A3 (en) Aging biomarkers
WO2011028099A8 (en) Method for preparing an invasive test of an egg and for determining a gender of an embryo in an egg
WO2013044187A3 (en) Detecting ovarian cancer
MX2013008026A (en) Microporous membrane and manufacturing method therefor.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12723637

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12723637

Country of ref document: EP

Kind code of ref document: A2